CMS finalizes Medicare drug price negotiation rule covering up to 20 drugs a year

CMS made Medicare drug price negotiation permanent by rule, with up to 20 drugs a year starting in 2029.

Objective Facts

The Centers for Medicare & Medicaid Services issued a final rule on Nov. 5, 2026, that writes the Medicare Drug Price Negotiation Program into federal regulation starting with prices effective in 2029. Negotiation for 2026 through 2028 ran on agency guidance, and the new rule takes effect Dec. 5, 2026, according to the CMS fact sheet. By Feb. 1, 2027, CMS will select up to 20 more drugs covered under Part D or Part B for the fourth cycle, and it may also pick previously negotiated drugs for renegotiation. Pharmaceutical Commerce reported that CMS received about 11,330 comment letters and finalized, over objections from drugmakers and more than 50 lawmakers, a policy that treats certain new combination formulations as part of the older drug. CMS gave no dollar savings estimate for the rule, Jolt Journal noted.

Left-Leaning Perspective

Mainstream left coverage of the final rule was thin in what this search could read. STAT's John Wilkerson reported in June that the proposal aimed to close a loophole drugmakers use to avoid negotiation, but the full story is paywalled. The Center for American Progress, a left-leaning think tank, argued in November 2025 that negotiation is working and that CMS should close loopholes and lift caps on how many drugs it negotiates. That position supports the combination drug policy CMS just finalized, though the CAP piece predates the rule.

Right-Leaning Perspective

Right-leaning coverage centered on the combination drug policy before it was finalized. Fox News Digital's Sophia Compton reported in September that more than 50 lawmakers from both parties, led in part by Republican Reps. John Joyce and Darin LaHood, asked Oz to drop it, saying it would hurt cancer patients who benefit from quick injections instead of long IV infusions. Former Congressional Budget Office director Dan Crippen, writing in CT Examiner in October, argued that the IRA's price controls are already cutting research and cited the same proposed policy as a further risk. CMS finalized the policy anyway.

Deep Dive

The 2022 Inflation Reduction Act told CMS to run the first three negotiation cycles through guidance, and Pharmaceutical Commerce reported that this requirement ends after 2028. The Nov. 5 rule fills that gap. It applies to the fourth cycle, when CMS will name up to 20 drugs by Feb. 1, 2027, for prices starting in 2029, and it also governs drugs picked in earlier rounds from 2029 on. Prior cycles covered 10 drugs for 2026, 15 for 2027 and 15 for 2028. CMS waived the usual 60-day delay for major rules so the rule takes effect Dec. 5. CMS's case is that the rule gives drugmakers predictability while closing a path to avoid negotiated prices. The most contested piece, the fixed combination drug policy, targets products like IV biologics reformulated with hyaluronidase for injection. Pharmaceutical Commerce reported that commenters said the policy discounts development costs and falls hardest on small biotechs, and the lawmakers' letter said CMS actuaries had not shown meaningful savings. CMS did not release a savings figure, which leaves that claim untested in public. Halozyme, the main supplier of hyaluronidase technology, told investors it expects zero to minimal royalty impact through at least 2035, which suggests the near-term commercial effect may be smaller than the political fight implies. Hospitals have their own concern: the American Hospital Association asked CMS to require point-of-sale pricing rather than retrospective rebates, and the rule leaves payment mechanics to later guidance. The next markers are fall 2026 guidance on putting 2028 negotiated prices into effect, including for Part B drugs, and a 2027 rulemaking on how those prices are paid for 2029 and later. The Feb. 1, 2027, drug list will show how far the combination drug policy reaches. Legal challenges are possible, since PhRMA sued CMS in October over a separate Part B pricing model, according to a related item on the Global Relay Intelligence & Practice site, though no suit against this rule had been reported.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

CMS finalizes Medicare drug price negotiation rule covering up to 20 drugs a year

CMS made Medicare drug price negotiation permanent by rule, with up to 20 drugs a year starting in 2029.

Nov 7, 2026· Updated Nov 8, 2026
What's Going On
  • CMS issued final rule CMS-4215-F on Nov. 5, 2026, putting the Medicare Drug Price Negotiation Program into regulation for prices effective in 2029 and later, according to the CMS fact sheet.
  • The rule takes effect Dec. 5, 2026, and CMS will pick up to 20 more Part D or Part B drugs, plus drugs for renegotiation, by Feb. 1, 2027, CMS and Becker's Hospital Review reported.
  • CMS kept its contested policy that groups certain fixed combination drugs, such as an IV biologic reformulated with hyaluronidase for injection, with the original product, Pharmaceutical Commerce reported.
  • The rule also sets a temporary price floor for qualifying small biotech drugs in 2029 and 2030 and caps what Part D plans pay pharmacies at the maximum fair price plus dispensing fees.
  • CMS Administrator Mehmet Oz said the rule gives the agency more tools to negotiate, while the Partnership to Fight Chronic Disease said the combination drug policy threatens innovation.
Far Left: Common Dreams framed Medicare negotiation as a Democratic achievement that the Trump administration had both weakened and claimed credit for.
Left: STAT described the June proposal as an effort to close a negotiation loophole for drugs that add a new ingredient.
Moderate: Becker's Hospital Review said CMS presented the rule as giving drugmakers a more predictable process.
Right: The lawmakers' letter, reported by Fox News Digital, said CMS actuaries had not shown the policy would produce meaningful savings.
Far Right: No far-right coverage of the Nov. 5 rule was found.
✓ Common Ground
Some voices on the left, such as CAP's Neda Ashtari, and the Trump CMS under Mehmet Oz share the view that drugmakers should not be able to delay negotiation by reformulating existing drugs.
Several lawmakers across the aisle, including Republican Rep. John Joyce and Democratic Rep. Jim Costa, signed the same letter opposing the combination drug policy, according to Fox News Digital.
The Trump administration now defends a negotiation program created by a 2022 law that passed with no Republican votes, as Common Dreams noted, and its rule makes that program permanent.
◆ All Sources (14)
CMS - CMS Final Rule Strengthens Supports Lasting Drug SavingsCMS - Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Final Rule (CMS-4215-F)Becker's Hospital Review - CMS to make drug price negotiation framework permanentPharmaceutical Commerce - How CMS' Final Negotiation Rule Treats New Drug FormulationsAHA News - CMS finalizes rule to codify Medicare Drug Price Negotiation ProgramJolt Journal - Medicare Drug Price Negotiation Final Rule: What ChangesGRIP - CMS finalizes contested Medicare drug price negotiation ruleTradingKey - Halozyme Reaffirms Minimal Royalty Impact Through 2035 Under CMS RuleCenter for American Progress - Medicare Negotiation Is Working, but the Trump Administration's Rollbacks Diminish Potential SavingsCommon Dreams - Biden-Era Law That Trump Has Attacked Delivers Price Cuts for 15 More Drugs Under MedicarePublic Citizen - Policymakers Must Defend Medicare Drug Price Negotiations against Big PharmaFox News - Trump CMS faces bipartisan pushback over Medicare proposal tied to Biden-era drug pricing lawCT Examiner - Four Years Later, What's the Damage from the IRA's Drug Price Controls?Partnership to Fight Chronic Disease - CMS Final Rule Threatens Innovation and Future Treatment Options for Patients
Objective Deep Dive

The 2022 Inflation Reduction Act told CMS to run the first three negotiation cycles through guidance, and Pharmaceutical Commerce reported that this requirement ends after 2028. The Nov. 5 rule fills that gap. It applies to the fourth cycle, when CMS will name up to 20 drugs by Feb. 1, 2027, for prices starting in 2029, and it also governs drugs picked in earlier rounds from 2029 on. Prior cycles covered 10 drugs for 2026, 15 for 2027 and 15 for 2028. CMS waived the usual 60-day delay for major rules so the rule takes effect Dec. 5.

CMS's case is that the rule gives drugmakers predictability while closing a path to avoid negotiated prices. The most contested piece, the fixed combination drug policy, targets products like IV biologics reformulated with hyaluronidase for injection. Pharmaceutical Commerce reported that commenters said the policy discounts development costs and falls hardest on small biotechs, and the lawmakers' letter said CMS actuaries had not shown meaningful savings. CMS did not release a savings figure, which leaves that claim untested in public. Halozyme, the main supplier of hyaluronidase technology, told investors it expects zero to minimal royalty impact through at least 2035, which suggests the near-term commercial effect may be smaller than the political fight implies. Hospitals have their own concern: the American Hospital Association asked CMS to require point-of-sale pricing rather than retrospective rebates, and the rule leaves payment mechanics to later guidance.

The next markers are fall 2026 guidance on putting 2028 negotiated prices into effect, including for Part B drugs, and a 2027 rulemaking on how those prices are paid for 2029 and later. The Feb. 1, 2027, drug list will show how far the combination drug policy reaches. Legal challenges are possible, since PhRMA sued CMS in October over a separate Part B pricing model, according to a related item on the Global Relay Intelligence & Practice site, though no suit against this rule had been reported.

◈ Tone Comparison

Supporters of negotiation use moral language about drug companies: Common Dreams carried Sen. Ron Wyden's description of Democrats taking on the drug industry. Critics talk about patients and research, with the lawmakers' letter reported by Fox News Digital saying cancer patients deserve the most advanced new therapies. CMS's own language stays technical, describing the combination drug policy as protecting program integrity.